Chiusura precedente | 2,1000 |
Aperto | 2,0500 |
Denaro | 2,6000 |
Domanda | 4,7000 |
Prezzo d'esercizio | 15,00 |
Scadenza | 2024-07-05 |
Min-Max giorno | 2,0500 - 2,1000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 190 |
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below. Michael S. Weiss, Chairman and Chief Executive Officer of
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy. Abstr
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ETNEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 2023 Cantor Global Healthcare Conference, being held at the Intercontinental Barclay Hotel, in New York City on September 26 - 28, 2023. The fireside chat is scheduled to take place on Tuesday, September 26, 2023, at 12:25 PM ET. A